Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Novo Nordisk is betting big on AI, partnering with Anthropic to use its Claude models in drug discovery and R&D workflows. The Danish pharma giant already uses Claude to automate trial reports and cut patient documentation timelines from months to minutes. The move reflects a broader pharma industry push to harness AI for faster, more efficient drug development.
Novo Nordisk teams up with Anthropic to turbocharge drug discovery using AI
Novo Nordisk has joined forces with AI company Anthropic to integrate Claude models into its research and development workflows. The partnership aims to tackle complex scientific problems, accelerate drug discovery, and unlock new insights into human biology and drug mechanics — areas where AI's reasoning capabilities could offer a genuine edge beyond simple automation.
The Wegovy maker isn't starting from scratch here. Novo already uses Claude to automate clinical trial report generation and has slashed patient documentation timelines from months to mere minutes. The next phase will expand that footprint, including using Anthropic's frontier models to strengthen AI-driven software development across the company.
Key Takeaways:
Why it matters: As drug development costs soar and timelines stretch, AI partnerships like this one signal a potential inflection point for how medicines are discovered — with real implications for how quickly new treatments could reach patients.
